Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis

Background: Several studies have revealed the potential use of tocilizumab in treating COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab may provide clinical benefits for cytokine release syndrome in COVID-19 patients. Methods: We searched for relevant studies in Pu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nugroho, Cahyo Wibisono, Suryantoro, Satriyo Dwi, Yuliasih, Yuliasih, Rosyid, Alfian Nur, Asmarawati, Tri Pudy, Andrianto, Lucky, Setiawan, Herley Windo, Mahdi, Bagus Aulia, Windradi, Choirina, Agustin, Esthiningrum Dewi, Fajar, Jonny Karunia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953915/
https://www.ncbi.nlm.nih.gov/pubmed/33763201
http://dx.doi.org/10.12688/f1000research.45046.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953915/
https://www.ncbi.nlm.nih.gov/pubmed/33763201
http://dx.doi.org/10.12688/f1000research.45046.1

Ejemplares similares